{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T22:55:52Z","timestamp":1781045752788,"version":"3.54.1"},"reference-count":80,"publisher":"Walter de Gruyter GmbH","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,12,1]]},"abstract":"Abstract<\/jats:title>Background<\/jats:title>Peritoneal carcinomatosis in colorectal cancer is an advanced stage of the disease where improved survival can be attained whenever the resection associated with hyperthermic intreperitoneal chemotherapy is possible. In unresectable cases, systemic chemotherapy is administered to obtain conversion to resectability but results have not yet been clearly evaluated. Local chemotherapy in this setting has been proven useful in several similar situations. The aim of the present pilot study was to evaluate the feasibility of pre-operative intraperitoneal chemotherapy with oxaliplatin in these patients.<\/jats:p><\/jats:sec>Methods<\/jats:title>Six patients with unresectable peritoneal disease of colorectal origin were included in the study. An intraperitoneal implantable chamber catheter was inserted during the laparotomy that evaluated the extent of the peritoneal disease (peritoneal carcinomatosis index 25 to 39). Patients then underwent intraperitoneal chemotherapy with oxaliplatin 85\u2006mg\/m2<\/jats:sup> in combination with systemic chemotherapy (FOLFIRI or simplified LV5FU) and a targeted therapy every 2 weeks.<\/jats:p><\/jats:sec>Results<\/jats:title>Two catheter perfusion incidents were reported due to the abdominal wall thickness. Two patients completed the four intraperitoneal (IP) chemotherapy cycles without major toxicity. One patient developed grade 3 or 4 diarrhea requiring a short intensive care unit (ICU) stay, though it is not clear whether the event was induced by intravenous irinotecan, IP oxaliplatin or the combination of both. Grade 3 fatigue and abdominal pain were also recorded. For one patient with aggressive disease, best supportive care was initiated after the first course of chemotherapy.<\/jats:p><\/jats:sec>Conclusions<\/jats:title>Our study is the first to assess intraperitoneal oxaliplatin-based chemotherapy in the preoperative setting for patients with unresectable peritoneal metastases. The tolerance was acceptable for 85\u2006mg\/m2<\/jats:sup> IP oxaliplatin combined with systemic therapy in these patients. Our results justify carrying on with a phase I\/II trial to determine the recommended dose of oxaliplatin in this clinical context and its efficacy.<\/jats:p><\/jats:sec>","DOI":"10.1515\/pp-2016-0018","type":"journal-article","created":{"date-parts":[[2016,12,30]],"date-time":"2016-12-30T10:01:26Z","timestamp":1483092086000},"page":"209-215","source":"Crossref","is-referenced-by-count":13,"title":["Preoperative intraperitoneal oxaliplatin for unresectable peritoneal carcinomatosis of colorectal origin: a pilot study"],"prefix":"10.1515","volume":"1","author":[{"given":"Olivia","family":"Sgarbura","sequence":"first","affiliation":[{"name":"1Surgical Oncology Department, Institut r\u00e9gional du Cancer de Montpellier (ICM), 208 avenue des Apothicaires, 34298 Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Samalin","sequence":"additional","affiliation":[{"name":"2Medical Oncology Department, Institut r\u00e9gional du Cancer de Montpellier (ICM), Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Carrere","sequence":"additional","affiliation":[{"name":"3Surgical Oncology Department, Institut r\u00e9gional du Cancer de Montpellier (ICM), Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibault","family":"Mazard","sequence":"additional","affiliation":[{"name":"2Medical Oncology Department, Institut r\u00e9gional du Cancer de Montpellier (ICM), Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne de","family":"Forges","sequence":"additional","affiliation":[{"name":"4Clinical Research Unit, Institut r\u00e9gional du Cancer de Montpellier (ICM), Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Alline","sequence":"additional","affiliation":[{"name":"3Surgical Oncology Department, Institut r\u00e9gional du Cancer de Montpellier (ICM), Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-H\u00e9l\u00e8ne","family":"Pissas","sequence":"additional","affiliation":[{"name":"3Surgical Oncology Department, Institut r\u00e9gional du Cancer de Montpellier (ICM), Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"Portales","sequence":"additional","affiliation":[{"name":"2Medical Oncology Department, Institut r\u00e9gional du Cancer de Montpellier (ICM), Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Ychou","sequence":"additional","affiliation":[{"name":"2Medical Oncology Department, Institut r\u00e9gional du Cancer de Montpellier (ICM), Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Quenet","sequence":"additional","affiliation":[{"name":"3Surgical Oncology Department, Institut r\u00e9gional du Cancer de Montpellier (ICM), Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","reference":[{"key":"ref01","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/S0140-6736(13)61649-9","article-title":"Colorectal cancer","volume":"383","year":"2014","journal-title":"Lancet"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nrclinonc.2015.140","article-title":"Advances in the care of patients with mucinous colorectal cancer","volume":"13","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s10120-010-0547-2","article-title":"Pilot study of a combination of S-1 and paclitaxel for patients with peritoneal metastasis from gastric cancer","volume":"13","year":"2010","journal-title":"Gastric Cancer"},{"key":"ref811","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1200\/JCO.2008.20.1301","article-title":"Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma","volume":"27","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref251","article-title":"Prognostic similarities and differences in optimally resected liver metastases and peritoneal metastases from colorectal cancers","year":"2015","journal-title":"Ann Surg"},{"key":"ref441","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.ejca.2012.12.027","article-title":"Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012","volume":"49","year":"2013","journal-title":"Eur J Cancer"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1200\/JCO.2004.10.012","article-title":"Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study","volume":"22","year":"2004","journal-title":"J Clin Oncol"},{"key":"ref381","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1200\/JCO.2008.20.1301","article-title":"Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma","volume":"27","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref281","first-page":"29","article-title":"Surgical technology and pharmacology of hyperthermic perioperative chemotherapy","volume":"7","year":"2016","journal-title":"J Gastrointest Oncol"},{"key":"ref651","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1002\/cncr.28204","article-title":"A phase 2 trial of intravenous and intraperitoneal paclitaxel combined with S-1 for treatment of gastric cancer with macroscopic peritoneal metastasis.","volume":"119","year":"2013","journal-title":"Cancer"},{"key":"ref291","first-page":"960","article-title":"Intraperitoneal and intravenous chemotherapy in peritoneal carcinomatosis","volume":"59","year":"2012","journal-title":"Hepatogastroenterology"},{"key":"ref641","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000358379","article-title":"Intraperitoneal paclitaxel is useful as adjuvant chemotherapy for advanced gastric cancer with serosal exposure","volume":"7","year":"2014","journal-title":"Case Rep Oncol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.ejca.2012.12.027","article-title":"Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012","volume":"49","year":"2013","journal-title":"Eur J Cancer"},{"key":"ref581","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/jso.22057","article-title":"Intraperitoneal docetaxel combined with S-1 for advanced gastric cancer with peritoneal dissemination","volume":"105","year":"2012","journal-title":"J Surg Oncol"},{"key":"ref391","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S1470-2045(03)01074-X","article-title":"Intraperitoneal antineoplastic drug delivery: rationale and results","volume":"4","year":"2003","journal-title":"Lancet Oncol"},{"key":"ref511","doi-asserted-by":"crossref","first-page":"2958","DOI":"10.1245\/s10434-015-4387-5","article-title":"Extent of colorectal peritoneal carcinomatosis: attempt to define a threshold above which HIPEC does not offer survival benefit: a comparative study","volume":"22","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"2958","DOI":"10.1245\/s10434-015-4387-5","article-title":"Extent of colorectal peritoneal carcinomatosis: attempt to define a threshold above which HIPEC does not offer survival benefit: a comparative study","volume":"22","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"ref131","first-page":"1335","article-title":"Feasibility study of S-1 and intraperitoneal docetaxel combination chemotherapy for gastric cancer with peritoneal dissemination","volume":"30","year":"2010","journal-title":"Anticancer Res"},{"key":"ref541","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","year":"2006","journal-title":"N Engl J Med"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1002\/cncr.28204","article-title":"A phase 2 trial of intravenous and intraperitoneal paclitaxel combined with S-1 for treatment of gastric cancer with macroscopic peritoneal metastasis.","volume":"119","year":"2013","journal-title":"Cancer"},{"key":"ref761","first-page":"1","article-title":"Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer","volume":"62","year":"1978","journal-title":"Cancer Treat Rep"},{"key":"ref431","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/S0140-6736(13)61649-9","article-title":"Colorectal cancer","volume":"383","year":"2014","journal-title":"Lancet"},{"key":"ref711","first-page":"29","article-title":"Surgical technology and pharmacology of hyperthermic perioperative chemotherapy","volume":"7","year":"2016","journal-title":"J Gastrointest Oncol"},{"key":"ref481","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1038\/bjc.2014.419","article-title":"Cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy improves survival in patients with colorectal peritoneal metastases compared with systemic chemotherapy alone","volume":"111","year":"2014","journal-title":"Br J Cancer"},{"key":"ref501","doi-asserted-by":"crossref","first-page":"5608","DOI":"10.1002\/cncr.25356","article-title":"Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients","volume":"116","year":"2010","journal-title":"Cancer"},{"key":"ref621","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/jso.21324","article-title":"Safety and efficacy of bidirectional chemotherapy for treatment of patients with peritoneal dissemination from gastric cancer: Selection for cytoreductive surgery","volume":"100","year":"2009","journal-title":"J Surg Oncol"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1245\/s10434-011-1770-8","article-title":"Neoadjuvant intraperitoneal and systemic chemotherapy for gastric cancer patients with peritoneal dissemination","volume":"18","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"ref571","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1245\/s10434-011-1770-8","article-title":"Neoadjuvant intraperitoneal and systemic chemotherapy for gastric cancer patients with peritoneal dissemination","volume":"18","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"ref271","first-page":"309417","volume":"2012","year":"2012","journal-title":"Cytoreductive surgery plus hyperthermic perioperative chemotherapy for selected patients with peritoneal metastases from colorectal cancer: a new standard of care or an experimental approach?"},{"key":"ref661","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1007\/s10147-008-0836-5","article-title":"Pilot study of intraperitoneal administration of paclitaxel and oral S-1 for patients with peritoneal metastasis due to advanced gastric cancer","volume":"13","year":"2008","journal-title":"Int J Clin Oncol"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"491","DOI":"10.3892\/ol.2014.2651","article-title":"DCF intraperitoneal and intravenous dual chemotherapy regimen for advanced gastric cancer: A feasibility study","volume":"9","year":"2015","journal-title":"Oncol Lett"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","year":"2006","journal-title":"N Engl J Med"},{"key":"ref821","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S1470-2045(03)01074-X","article-title":"Intraperitoneal antineoplastic drug delivery: rationale and results","volume":"4","year":"2003","journal-title":"Lancet Oncol"},{"key":"ref561","first-page":"1335","article-title":"Feasibility study of S-1 and intraperitoneal docetaxel combination chemotherapy for gastric cancer with peritoneal dissemination","volume":"30","year":"2010","journal-title":"Anticancer Res"},{"key":"ref531","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nrclinonc.2015.140","article-title":"Advances in the care of patients with mucinous colorectal cancer","volume":"13","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"ref771","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1159\/000209277","article-title":"Phase I pharmacokinetic study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer","volume":"76","year":"2009","journal-title":"Oncology"},{"key":"ref631","doi-asserted-by":"crossref","first-page":"491","DOI":"10.3892\/ol.2014.2651","article-title":"DCF intraperitoneal and intravenous dual chemotherapy regimen for advanced gastric cancer: A feasibility study","volume":"9","year":"2015","journal-title":"Oncol Lett"},{"key":"ref851","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/annonc\/mdf019","article-title":"Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution","volume":"13","year":"2002","journal-title":"Ann Oncol"},{"key":"ref231","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1007\/s10147-008-0836-5","article-title":"Pilot study of intraperitoneal administration of paclitaxel and oral S-1 for patients with peritoneal metastasis due to advanced gastric cancer","volume":"13","year":"2008","journal-title":"Int J Clin Oncol"},{"key":"ref401","first-page":"153","article-title":"Current status of intraperitoneal antineoplastic drug delivery","volume":"134","year":"2007","journal-title":"Cancer Treat Res"},{"key":"ref591","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s00280-013-2122-0","article-title":"Phase I\/II study of intraperitoneal docetaxel plus S-1 for the gastric cancer patients with peritoneal carcinomatosis","volume":"71","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref741","doi-asserted-by":"crossref","first-page":"F433","DOI":"10.1152\/ajprenal.00313.2004","article-title":"The transport barrier in intraperitoneal therapy","volume":"288","year":"2005","journal-title":"Am J Physiol Renal Physiol"},{"key":"ref611","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.ejso.2006.03.007","article-title":"Neoadjuvant treatment of gastric cancer with peritoneal dissemination","volume":"32","year":"2006","journal-title":"Eur J Surg Oncol"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s00280-013-2122-0","article-title":"Phase I\/II study of intraperitoneal docetaxel plus S-1 for the gastric cancer patients with peritoneal carcinomatosis","volume":"71","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref261","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1245\/s10434-008-0173-y","article-title":"Comprehensive management of disseminated colorectal cancer","volume":"15","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"ref491","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1200\/JCO.2004.10.012","article-title":"Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study","volume":"22","year":"2004","journal-title":"J Clin Oncol"},{"key":"ref801","first-page":"e129","article-title":"Hepatic arterial infusion pump chemotherapy in the management of colorectal liver metastases: expert consensus statement","volume":"21","year":"2014","journal-title":"Curr Oncol"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/jso.22057","article-title":"Intraperitoneal docetaxel combined with S-1 for advanced gastric cancer with peritoneal dissemination","volume":"105","year":"2012","journal-title":"J Surg Oncol"},{"key":"ref331","first-page":"1","article-title":"Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer","volume":"62","year":"1978","journal-title":"Cancer Treat Rep"},{"key":"ref701","first-page":"309417","volume":"2012","year":"2012","journal-title":"Cytoreductive surgery plus hyperthermic perioperative chemotherapy for selected patients with peritoneal metastases from colorectal cancer: a new standard of care or an experimental approach?"},{"key":"ref471","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/(SICI)1097-0142(20000115)88:2<358::AID-CNCR16>3.0.CO;2-O","article-title":"Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study","volume":"88","year":"2000","journal-title":"Cancer"},{"key":"ref461","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/bjs.8679","article-title":"Incidence prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer","volume":"99","year":"2012","journal-title":"Br J Surg"},{"key":"ref521","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1200\/JCO.2009.23.9285","article-title":"Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study","volume":"28","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref601","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/annonc\/mdp260","article-title":"Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis","volume":"21","year":"2010","journal-title":"Ann Oncol"},{"key":"ref691","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1245\/s10434-008-0173-y","article-title":"Comprehensive management of disseminated colorectal cancer","volume":"15","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"ref751","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/978-1-4613-1247-5_4","article-title":"Peritoneal-plasma barrier","volume":"82","year":"1996","journal-title":"Cancer Treat Res"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1200\/JCO.2009.23.9285","article-title":"Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study","volume":"28","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref311","doi-asserted-by":"crossref","first-page":"F433","DOI":"10.1152\/ajprenal.00313.2004","article-title":"The transport barrier in intraperitoneal therapy","volume":"288","year":"2005","journal-title":"Am J Physiol Renal Physiol"},{"key":"ref21","first-page":"693","article-title":"Abdominal metastases from colorectal cancer: intraperitoneal therapy","volume":"6","year":"2015","journal-title":"J Gastrointest Oncol"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.ejso.2006.03.007","article-title":"Neoadjuvant treatment of gastric cancer with peritoneal dissemination","volume":"32","year":"2006","journal-title":"Eur J Surg Oncol"},{"key":"ref721","first-page":"960","article-title":"Intraperitoneal and intravenous chemotherapy in peritoneal carcinomatosis","volume":"59","year":"2012","journal-title":"Hepatogastroenterology"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/jso.21324","article-title":"Safety and efficacy of bidirectional chemotherapy for treatment of patients with peritoneal dissemination from gastric cancer: Selection for cytoreductive surgery","volume":"100","year":"2009","journal-title":"J Surg Oncol"},{"key":"ref351","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1159\/000323272","article-title":"Phase I study of biweekly intravenous paclitaxel plus intraperitoneal cisplatin and paclitaxel for gastric cancer with peritoneal metastasis","volume":"79","year":"2010","journal-title":"Oncology"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1038\/bjc.2014.419","article-title":"Cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy improves survival in patients with colorectal peritoneal metastases compared with systemic chemotherapy alone","volume":"111","year":"2014","journal-title":"Br J Cancer"},{"key":"ref421","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/annonc\/mdf019","article-title":"Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution","volume":"13","year":"2002","journal-title":"Ann Oncol"},{"key":"ref791","first-page":"S10","article-title":"S-1 plus intravenous and intraperitoneal paclitaxel for gastric cancer with peritoneal metastasis","volume":"5","year":"2012","journal-title":"Gastrointest Cancer Res"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"5608","DOI":"10.1002\/cncr.25356","article-title":"Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients","volume":"116","year":"2010","journal-title":"Cancer"},{"key":"ref371","first-page":"e129","article-title":"Hepatic arterial infusion pump chemotherapy in the management of colorectal liver metastases: expert consensus statement","volume":"21","year":"2014","journal-title":"Curr Oncol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/(SICI)1097-0142(20000115)88:2<358::AID-CNCR16>3.0.CO;2-O","article-title":"Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study","volume":"88","year":"2000","journal-title":"Cancer"},{"key":"ref781","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1159\/000323272","article-title":"Phase I study of biweekly intravenous paclitaxel plus intraperitoneal cisplatin and paclitaxel for gastric cancer with peritoneal metastasis","volume":"79","year":"2010","journal-title":"Oncology"},{"key":"ref671","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s10120-010-0547-2","article-title":"Pilot study of a combination of S-1 and paclitaxel for patients with peritoneal metastasis from gastric cancer","volume":"13","year":"2010","journal-title":"Gastric Cancer"},{"key":"ref681","article-title":"Prognostic similarities and differences in optimally resected liver metastases and peritoneal metastases from colorectal cancers","year":"2015","journal-title":"Ann Surg"},{"key":"ref341","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1159\/000209277","article-title":"Phase I pharmacokinetic study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer","volume":"76","year":"2009","journal-title":"Oncology"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/bjs.8679","article-title":"Incidence prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer","volume":"99","year":"2012","journal-title":"Br J Surg"},{"key":"ref321","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/978-1-4613-1247-5_4","article-title":"Peritoneal-plasma barrier","volume":"82","year":"1996","journal-title":"Cancer Treat Res"},{"key":"ref211","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000358379","article-title":"Intraperitoneal paclitaxel is useful as adjuvant chemotherapy for advanced gastric cancer with serosal exposure","volume":"7","year":"2014","journal-title":"Case Rep Oncol"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/annonc\/mdp260","article-title":"Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis","volume":"21","year":"2010","journal-title":"Ann Oncol"},{"key":"ref451","first-page":"693","article-title":"Abdominal metastases from colorectal cancer: intraperitoneal therapy","volume":"6","year":"2015","journal-title":"J Gastrointest Oncol"},{"key":"ref361","first-page":"S10","article-title":"S-1 plus intravenous and intraperitoneal paclitaxel for gastric cancer with peritoneal metastasis","volume":"5","year":"2012","journal-title":"Gastrointest Cancer Res"},{"key":"ref831","first-page":"153","article-title":"Current status of intraperitoneal antineoplastic drug delivery","volume":"134","year":"2007","journal-title":"Cancer Treat Res"}],"container-title":["Pleura and Peritoneum"],"original-title":[],"link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/pp\/1\/4\/article-p209.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/pp-2016-0018\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T04:25:37Z","timestamp":1619065537000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/pp-2016-0018\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,1]]},"references-count":80,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.1515\/pp-2016-0018","relation":{},"ISSN":["2364-7671","2364-768X"],"issn-type":[{"value":"2364-7671","type":"print"},{"value":"2364-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,1]]}}}